Prenosis Secures $20 Million Funding for Diagnostic Innovations
In a significant stride towards advancing patient care, Prenosis, a leading biology-based technology firm, announced its successful completion of a $20 million Series A financing round alongside securing a $20 million contract from the Biomedical Advanced Research and Development Authority (BARDA). This dual achievement marks a pivotal moment in Prenosis' mission to enhance integrated diagnostics and therapeutics for critical health conditions.
Innovative Funding for Integrated Diagnostics
This round of financing, supported by notable private investors, is aimed at accelerating the commercial delivery of Prenosis' pioneering artificial intelligence-driven diagnostic tools. In particular, these funds will facilitate clinical trial enrollment, algorithm validation, and regulatory advancements, allowing Prenosis to expand its precision medicine platform to tackle health crises such as sepsis, pneumonia, acute heart failure, acute respiratory distress syndrome, and acute kidney injury.
Transforming Critical Care with AI
As Prenosis' CEO and co-founder, Bobby Reddy, Jr., PhD, highlighted, the investments position the company to revolutionize treatment outcomes for patients battling severe conditions. The funds will directly support the development of biology-based solutions that can significantly impact patient outcomes.
Strategic Partnerships Fuel Progress
Prenosis raised this capital with the backing of prominent investors like PACE Healthcare Capital, UC Investments, UCI Health Ventures, Labcorp Venture Fund, Global Health Investment Corporation (GHIC), the Illinois Department of Commerce and Economic Opportunity (DCEO), and Carle Health. This collective effort demonstrates the confidence in Prenosis' innovative approach, particularly through the development of the Sepsis ImmunoScore, recognized as the first FDA-authorized AI diagnostic tool for sepsis.
Recognizing the Urgency of Sepsis
Sepsis remains a pressing health issue, claiming more lives annually than all cancers combined. The complexity of diagnosing and treating sepsis warrants effective solutions, as noted by Julia Monfrini Peev, PACE Healthcare Capital Managing Partner. The Sepsis ImmunoScore embodies the culmination of initiatives aimed at empowering healthcare providers with reliable and actionable information.
BARDA’s Role in Advancing Research
The $20 million contract from BARDA, part of the Type to Treat Program, focuses on pivotal studies to strengthen the precision medicine platform. By enrolling approximately 800 patients with severe respiratory infections, the study aims to evaluate corticosteroid therapy's effectiveness alongside Prenosis' AI-powered diagnostic tools, ultimately enhancing treatment strategies.
Building a Clinical Trial Network
Prenosis’ commitment extends to integrating its Immunix™ platform within top academic medical centers across the country, establishing a groundbreaking precision medicine clinical trial network. This initiative will allow swift identification and participation of eligible patients in cutting-edge therapeutic trials, fostering innovation in the treatment of critical conditions.
A Vision for the Future of Healthcare
As Carlos Lopez-Espina, SVP of Research and Development at Prenosis, expressed, this program exemplifies their innovative approach aimed at delivering personalized care. By leveraging AI diagnostics and targeted therapies, Prenosis is at the forefront of addressing the unique needs of each patient.
Acknowledging Achievements
In addition to the new funding, Prenosis has continually gained recognition, receiving multiple awards for innovation and contributions to healthcare. Notable accolades include honors from Chicago Innovation and TIME for the Sepsis ImmunoScore, highlighting the company’s impact in the field of diagnostic tools.
About Prenosis, Inc.
Prenosis is a pioneering company focused on transforming the standard of care for critical conditions through integrated diagnostics and therapeutics. With a mission to personalize healthcare, Prenosis utilizes AI and deep data to create innovative solutions that enhance clinical diagnosis and treatment, going beyond conventional methods. The Immunix™ platform powers a suite of predictive diagnostics, including the Sepsis ImmunoScore, underscoring Prenosis’ commitment to improving patient health outcomes.
Frequently Asked Questions
What recent funding did Prenosis announce?
Prenosis announced a total funding of $20 million from a Series A round and a contract from BARDA.
What is the significance of the Sepsis ImmunoScore?
The Sepsis ImmunoScore is the first FDA-authorized AI diagnostic tool for sepsis aimed at improving timely diagnosis and treatment.
How will the BARDA contract advance research?
The BARDA contract will support pivotal studies evaluating corticosteroid therapies for patients with severe respiratory infections.
What are the future plans for Prenosis' clinical network?
Prenosis plans to integrate its Immunix™ platform within top academic medical centers to establish a precision medicine clinical trial network.
What is Prenosis' mission?
Prenosis aims to redefine healthcare by personalizing diagnostics and therapeutics based on each patient's unique biological profile.
